Previous 10 | Next 10 |
– Presentations to be webcast on www.exelixis.com – Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will provide an overview of the company at the following investor conferences in December: Evercore ISI 2 nd Annual ...
There's a very good reason Peter Lynch is an investing legend: For the 13 years he ran the Fidelity Magellan Fund , he averaged a 29% annual return that consistently more than doubled the return of the S&P 500 . He published two books that shared his investing philosophy , One Up on Wal...
Exelixis, Inc. (EXEL) Stifel Healthcare Conference Call November 19, 2019 09:10 a.m. ET Company Representatives Mike Morrissey - Chief Executive Officer Chris Senner - Chief Financial Officer Susan Hubbard - Executive Vice President, Public Affairs, IR Andrew Peters - VP of Str...
The past six months have been rough for investors and the management team at Exelixis (NASDAQ: EXEL) . The stock sank nearly 40% from its high north of $24 in April to its recent range of $15. Today, however, sentiment appears to be shifting in Exelixis' favor. While the stock looked weak,...
Investment Thesis Having taken a deep dive look at Exelisis, I believe the negative share price reaction to the company's latest set of results, which out-performed expectations, was unwarranted. Overall, I believe the stock is undervalued. In this article I will address the concerns surroun...
– Presentation to be webcast on www.exelixis.com – Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the Stifel 2019 Healthcare Conference ...
Exelixis ( EXEL +0.8% ) announces that Health Canada has approved commercialization partner Ipsen Biopharmaceuticals Canada's ( OTCPK:IPSEY +0.3% ) marketing application for Cabometyx (cabozantinib) for the treatment of hepatocellular carcinoma in patients who have previously re...
Introduction My last article on Exelixis ( EXEL ) was nearly a year ago. Back then, I noted the looming competition (immunotherapy) in first-line renal cell carcinoma, Temporary slowing revenues may precede volatility in shares of Exelixis. Source: Clover Biotech Research ...
– Approval based on statistically significant and clinically meaningful overall survival benefit demonstrated in the CELESTIAL phase 3 pivotal trial – Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received Health Ca...
Shares of cancer specialist Exelixis (NASDAQ: EXEL) dropped by 12.6% in October, according to data from S&P Global Market Intelligence . Why did investors hit the exits last month? Despite a strong month for biotech stocks in general, Exelixis' shares were essentia...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...